Fuzeon

Fuzeon is a brand name of enfuvirtide, approved by the FDA in the following formulation(s):

FUZEON (enfuvirtide - injectable; subcutaneous)

• 
  Manufacturer: ROCHE
  
  Approval date: March 13, 2003
  
  Strength(s): 90MG/VIAL ^[RLD]

Has a generic version of Fuzeon been approved?

No. There is currently no therapeutically equivalent version of Fuzeon available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fuzeon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Synthetic peptide inhibitors of HIV transmission
  Patent 5,464,933
  Issued: November 7, 1995
  Inventor(s): Bolognesi; Dani P. & Matthews; Thomas J. & Wild; Carl T.
  Assignee(s): Duke University
  The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP-178 (SEQ ID:1) ptides corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP-178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
  
  Patent expiration dates:
  
  
  • June 7, 2013
    
  
  



• 
  Synthetic peptide inhibitors of HIV transmission
  Patent 6,133,418
  Issued: October 17, 2000
  Inventor(s): Bolognesi; Dani Paul & Matthews; Thomas James & Wild; Carl T.
  Assignee(s): Duke University
  The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention comprise DP-178 (SEQ ID:1) ptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LAI gp41 protein, and fragments, analogs and homologs of DP-178. The invention further relates to the uses of such peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
  
  Patent expiration dates:
  
  
  • November 17, 2014
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Treatment of HIV and other viral infections using combinatorial therapy
  Patent 6,475,491
  Issued: November 5, 2002
  Inventor(s): M. Ross; Johnson & Dennis Michael; Lambert
  Assignee(s): Trimeris, Inc.
  Novel antiviral combinations for the treatment or prevention of viral infections, in particular, HIV, are disclosed. This new antiviral therapy employs either DP-178 or DP-107, viral fusion inhibitors, in combination with at least one other antiviral therapeutic agent. The combinations of the invention are better than single therapies alone, and in certain cases are synergistic. The use of DP-178 or DP-107 is an ideal therapy to combine with another antiviral, given both the novel mechanism which this therapeutic blocks HIV transmission and the non-toxicity of the therapeutic.
  
  Patent expiration dates:
  
  
  • June 7, 2015
    
    ✓ 
    Patent use: TREATMENT OF HIV
  
  

See also...

• Fuzeon Consumer Information (Drugs.com)
• Fuzeon Consumer Information (Wolters Kluwer)
• Fuzeon Consumer Information (Cerner Multum)
• Fuzeon Advanced Consumer Information (Micromedex)
• Fuzeon AHFS DI Monographs (ASHP)
• Enfuvirtide Consumer Information (Wolters Kluwer)
• Enfuvirtide Consumer Information (Cerner Multum)
• Enfuvirtide Subcutaneous Advanced Consumer Information (Micromedex)
• Enfuvirtide AHFS DI Monographs (ASHP)